For the quarter ended September 2023, Texas Instruments (TXN) reported revenue of $4.53 billion, down 13.5% over the same period last year. EPS came in at $1.80, compared to $2.45 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $4.57 billion, representing a surprise of -0.77%. The company delivered an EPS surprise of -0.55%, with the consensus EPS estimate being $1.81.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Texas Instruments performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Other: $289 million versus the six-analyst average estimate of $362.38 million. The reported number represents a year-over-year change of -32.3%.
- Revenue- Embedded Processing: $890 million versus $887.05 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.4% change.
- Revenue- Analog: $3.35 billion compared to the $3.30 billion average estimate based on six analysts. The reported number represents a change of -16% year over year.
- Operating Profit- Analog: $1.50 billion versus the two-analyst average estimate of $1.59 billion.
- Operating Profit- Other: $130 million versus the two-analyst average estimate of $23.13 million.
- Operating Profit- Embedded Processing: $258 million versus the two-analyst average estimate of $290.36 million.
Shares of Texas Instruments have returned -9.1% over the past month versus the Zacks S&P 500 composite's -2.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s credited with a “watershed medical breakthrough” and is developing a bustling pipeline of other projects that could make a world of difference for patients suffering from diseases involving the liver, lungs, and blood. This is a timely investment that you can catch while it emerges from its bear market lows.
It could rival or surpass other recent Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners UpTexas Instruments Incorporated (TXN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20Q3%20Earnings%3A%20A%20Look%20at%20Key%20Metrics%20%7C%20Nasdaq&_biz_n=0&rnd=340361&cdn_o=a&_biz_z=1741992591819)
%20Q3%20Earnings%3A%20A%20Look%20at%20Key%20Metrics%20%7C%20Nasdaq&rnd=549089&cdn_o=a&_biz_z=1741992591824)
%20Q3%20Earnings%3A%20A%20Look%20at%20Key%20Metrics%20%7C%20Nasdaq&_biz_n=0&rnd=340361&cdn_o=a&_biz_z=1741992594819)
%20Q3%20Earnings%3A%20A%20Look%20at%20Key%20Metrics%20%7C%20Nasdaq&_biz_n=0&rnd=340361&cdn_o=a&_biz_z=1741992597820)